Furthermore, insights into the role of the B-cell receptor (BCR) signalling pathway have led to the development of targeted agents, such as Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 antagonists, which have significantly impacted the management of CLL [19]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.